---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114205"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:36:37.232711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics reports Q3 net loss $28.3M; cash $361.5M; clinical pipeline progressing

## Summary
- Net loss of $28.3M ($0.96 per share) vs $14.7M ($0.59) in Q3 2021.
- Cash and equivalents $361.5M at Sep 30, 2022 ($438.7M Dec 31, 2021); runway into 2025.
- R&D expenses $22.8M (up from $10.5M) driven by BT5528, BT8009, and platform costs.
- Received $10M option fee from Genentech for expansion of immuno-oncology collaboration.
- BT5528 showed 22% ORR in ovarian, 67% in urothelial; expansion enrollment on track for Q4 2022.

## SEC filing metadata
- accession: 0001104659-22-114205
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/0001104659-22-114205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/tm2229573d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114205
- JSON: https://secwatch.observer/filing/0001104659-22-114205.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114205.txt

## Key facts
- Earnings Releases
  BICYCLE THERAPEUTICS PLC reported the third quarter ended September 30, 2022 results: net income Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share, EPS $(0.96) basic and diluted net loss per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share
  - EPS: $(0.96) basic and diluted net loss per share
  - Result: reported results
  source text: Bicycle Therapeutics plc (the "Company") issued a press release announcing financial results for the fiscal quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/0001104659-22-114205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.